Please assess the completion status of the following clinical trial:

Trial Title: Effect of the Sequestrant Colesevelam in Bile Acid Diarrhoea

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient referred to Clinical Physiological/Nuclear Medicine departments for SeHCAT~* Suspected Bile acid diarrhoea~* Age \> 18 years and under 80 years~* women of fertile age must use safe contraception during the treatment part of the study~* Ability to give informed consent after written and oral information in Danish language~Exclusion Criteria:~* Inflammatory bowel disease, including microscopic colitis~* Investigator assessed debilitating chronic disease e.g. World Health Organisation performance score 3-5~* Prior treatment with colesevelam~* Treatment with laxatives or anti-diarrhoeal drugs during the study~  * Except for stable dose the last four weeks of psyllium husk and opioids for pain~* Breastfeeding women~* Crucial medication that cannot be separated appropriately from colesevelam~  * i.e. taken one hour before or 4 hours after colesevelam~* Oral anticoagulation, both warfarin, and new oral anticoagulation~* Treatment with cyclosporine within two months~* Bowel obstruction (subileus or ileus)~* Biliary obstruction~* Short bowel syndrome~* Bowel ostomy~* Allergy to colesevelam or its constituents~* Allergy to placebo constituents (excluding lactose)~* Investigator assessed high risk of non-compliance~* If on statin/fibrate medication, unwilling to pause medication between study visits 1 and 2

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Colesevelam, active arm (Type: EXPERIMENTAL): Colesevelam hydrochloride, 625mg tablets. Overencapsulated with DB caps AAA for blinding.~Oral use. Dose: 1, 2, or 3 capsules twice daily. Starting dose 2 capsules twice daily. Dose titration by specific criteria by a central study nurse Treatment duration 12 days
- Placebo (Type: PLACEBO_COMPARATOR): Inactive placebo tablets. Overencapsulated with DB caps AAA for blinding. Oral use. Dosage and treatment duration as specified for colesevelam

Based on this trial design, predict the completion outcome and termination type (if applicable).